BiotechTube

Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Secondary Hyperparathyroidism

Conditions

Secondary Hyperparathyroidism

Trial Timeline

Jul 1, 2014 → Feb 1, 2015

NCT ID
NCT02216656

About Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493

Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493 is a phase 2 stage product being developed by Kyowa Kirin for Secondary Hyperparathyroidism. The current trial status is completed. This product is registered under clinical trial identifier NCT02216656. Target conditions include Secondary Hyperparathyroidism.

What happened to similar drugs?

13 of 20 similar drugs in Secondary Hyperparathyroidism were approved

Approved (13) Terminated (0) Active (7)
✅Cinacalcet HClKyowa KirinApproved
✅Paricalcitol + CalcifediolAbbVieApproved
✅Paricalcitol + Darbepoetin alfaAbbVieApproved
✅RanibizumabNovartisApproved
✅BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273NovartisApproved
✅RanibizumabNovartisApproved
✅Sensipar® + Vitamin DAmgenApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02216656Phase 2Completed

Competing Products

20 competing products in Secondary Hyperparathyroidism

See all competitors
ProductCompanyStageHype Score
ASP7991 + Cinacalcet + PlaceboAstellas PharmaPhase 2
35
FycompaEisaiPre-clinical
26
FycompaEisaiPre-clinical
26
KHK7580 + KRN1493Kyowa KirinPhase 2/3
38
KHK7580Kyowa KirinPhase 1
29
KHK7580Kyowa KirinPhase 3
40
KHK7580Kyowa KirinPhase 3
40
Cinacalcet HClKyowa KirinApproved
43
KHK7580 + Cinacalcet HydrochlorideKyowa KirinPhase 3
40
dirucotide + PlaceboEli LillyPhase 2/3
38
dirucotideEli LillyPhase 2/3
30
Paricalcitol + CalcitriolAbbViePre-clinical
18
paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placeboAbbViePhase 3
40
Paricalcitol + CalcifediolAbbVieApproved
43
Paricalcitol + Darbepoetin alfaAbbVieApproved
43
Birabresib Dose 20 mgMerckPhase 1
21
Remibrutinib (blinded) + Placebo + Remibrutinib (Open label)NovartisPhase 3
47
RanibizumabNovartisApproved
43
BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273NovartisApproved
43
Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDTNovartisPhase 3
40